Trending now

Nakuja Expeditions Reveals New Custom Safari Packages…

Long Lake Camps Announces Exclusive 2025 Musical…

Road Freight Transport Drives Growth in Azerbaijan’s…

ToonieBet launches Casino and Sportsbook platform in…

Avazona Ltd.’s ‘Founders in Focus’ Hits #1…

Atelier Home Sets a New Standard for…

WEMADE and Redlab Games Unleash Blockbuster Web3…

Drug-Free Tennessee Wraps Up Powerful Month of…

Greenstar ATM Empowers Cannabis Dispensaries with New…

Civil Service Success Opens Enrollment for 2025…

Mrjung.net

  • Ethereum
    • Ethereum

      The Anatomy of Anonymity: How Dandelion Could Make…

      September 13, 2018

      Ethereum

      A Newly Launched Stablecoin You’ve Never Heard of…

      September 13, 2018

      Ethereum

      Bitstamp: An Overview of the Industry’s Oldest Active…

      September 13, 2018

      Ethereum

      Bitcoin Price Analysis: Strong Rally Tests Trend-Changing Behavior

      September 13, 2018

      Ethereum

      Bitcoin as a Privacycoin: This Tech is Making…

      September 13, 2018

  • Bitcoin
    • Bitcoin

      Abra CEO Believes Bitcoin ETF Eminent, SEC Just…

      September 13, 2018

      Bitcoin

      Mt. Gox Opens Rehabilitation Filing System to Corporate…

      September 13, 2018

      Bitcoin

      World Economic Forum and the Chinese Cryptocurrency Space

      September 13, 2018

      Bitcoin

      Federal Judge Applies Long Established Securities Law to…

      September 13, 2018

      Bitcoin

      Biking Across America, Crypto Cyclists Look to Raise…

      September 13, 2018

  • Markets
    • Markets

      OKEx Founder Released After Questioning in Connection With…

      September 13, 2018

      Markets

      Two-for-One: SEC Slaps Crypto Hedge Fund, Broker With…

      September 13, 2018

      Markets

      Ripple and R3 Reach Settlement in Year-Long Court…

      September 13, 2018

      Markets

      DevCon 4 Will Set the Stage for Ethereum’s…

      September 13, 2018

      Markets

      Stellar-Based Lightyear Acquires Chain, Forms New Entity

      September 13, 2018

  • Guides
    • Guides

      Bitcoin Magazine’s Week in Review: Lightning, Launches and…

      September 13, 2018

      Guides

      Equity Trust Builds New Frontier of Crypto-Based Retirement…

      September 13, 2018

      Guides

      Crypto, Blockchain Companies Shine in LinkedIn’s Top 50…

      September 13, 2018

      Guides

      Distributed Dialogues: Governance and Decentralized Platforms

      September 13, 2018

      Guides

      Battle of the Privacycoins: Why Dash Is Not…

      September 13, 2018

  • Analytic
    • Analytic

      Bitcoin crash: This man lost his savings when…

      September 13, 2018

      Analytic

      Bitcoin crash: This man lost his savings when…

      September 13, 2018

      Analytic

      Lightning Ramp and Casa Join Hands to Develop…

      September 13, 2018

      Analytic

      You Can Now Pay With Bitcoin Via Lightning…

      September 13, 2018

      Analytic

      Abra Supports SEPA Bank Transfers, Enabling Crypto Purchases…

      September 13, 2018

  • Exchange
    • Exchange

      IBM Introduces ‘World Wire’ Payment System on Stellar…

      September 13, 2018

      Exchange

      Lightning Is Made at the #LightningHackday Series in…

      September 13, 2018

      Exchange

      Pellentesque mattis ex eget malesuada consequat. Sed blandit…

      September 13, 2018

      Exchange

      Goldman Sachs Puts Plans for a Crypto Trading…

      September 13, 2018

      Exchange

      Pellentesque mattis ex eget malesuada consequat. Sed blandit…

      September 13, 2018

  • Contact
Mrjung.net
News

Bonus BioGroup Receives Approval to Expand Phase-II Clinical Trials for its COVID-19 Treatment to Medical Centers Across Israel

by Binary News NetworkAugust 22, 20210546

TEL AVIV, ISRAEL, 22 Aug 2021, ZEXPRWIRE, Bonus BioGroup LTD or “the Company” (BONS.TA), an Israeli clinical-stage biotechnology company, has received official approval from the Israeli Ministry of Health to expand its phase II clinical trials for its MesenCure treatment to health centers and hospitals nationwide. MesenCure leverages advances in cell therapy to treat COVID-19 patients suffering from life-threatening pneumonia, acute respiratory distress, and associated complications caused by the immune system’s hyper-inflammatory response (cytokine storm) to the virus. 

The Israeli Ministry of Health’s decision regarding MesenCure coincides with a dramatic surge in infections and hospitalizations fueled by the more infective Delta-variant, which threatens to swamp the public health system in Israel and worldwide.  Despite high rates of vaccination, current rates of infection are approaching those seen at the height of the pandemic. Consequently, as countries worldwide explore viable alternatives to broad economic shutdowns, focus has been redirected towards establishing a modus vivendi with COVID-19 that places emphasis on reducing the number of hospitalized and severely ill patients. 

As announced in May and July 2021, Bonus BioGroup’s phase I/II clianical trials saw complete success in treating severe COVID-19 patients at Haifa’s Rambam Health Care Campus.  All trial participants were admitted with severe COVID-19, and 90% suffered from comorbidities posing an elevated risk for serious illness, complications, and a mortality rate of over 35%.  Despite these significant complicating factors, patients were released from the hospital after a median duration of one day following the MesenCure treatment.

Notwithstanding the severe condition of participating patients upon admittance, each of the three MesenCure doses administered to patients resulted in a significant decrease of diffuse inflammation.  A cumulative effect was also recorded after administering each of the three doses in reducing the risk of multiorgan dysfunction, heart damage, kidney damage, and venous thromboembolism caused by the body’s hyperinflammatory response to the virus.

Beyond its direct impact on attenuating hyper-inflammation, MesenCure has proven highly successful in improving additional parameters such as patient prognosis, recovery, and the chance of survival.  Furthermore, patients reported improvements in subjective parameters, including mobility, self-care capacity, and routine operations performance. 

Given MesenCure’s seeming effectiveness in treating severe COVID-19 patients with pre-existing conditions and high-risk comorbidities, this novel treatment has been seized upon as a potential solution for relieving overburdened hospital systems. By doing so, MesenCure can help prevent the imposition of economically damaging measures such as general lockdowns or closures.  In the weeks since the conclusion of the phase I/II trial, Bonus BioGroup has moved onto a phase II clinical trial that will include up to 50 participants suffering from severe COVID-19 in order to continue evaluating the efficacy and safety of MesenCure. 

Hailing from the cutting-edge fields of regenerative medicine and cell therapy, Bonus BioGroup’s MesenCure consists of allogeneic mesenchymal stromal cells that have been primed to enhance their immunomodulatory capabilities.  Once injected into the patient, the cells target the inflamed lungs, depress the cytokine storm, and promote the healing of the respiratory system and other internal organs adversely affected by COVID-19.

Beyond its current application to infections by SARS-CoV-2 variants, MesenCure is potentially applicable to a range of additional conditions. These conditions include asthma, chronic obstructive pulmonary disease, and other lower respiratory tract diseases caused by viruses, bacterial infection, or exposure to chemical insults.  Above and beyond the current demand for COVID-19 therapeutic solutions, MesenCure’s potential global market is forecasted to exceed $43 billion by 2026. 

The decision to expand MesenCure’s phase II trial to medical centers across Israel is indicative of the high-hopes both private and public sector stakeholders have for the use of this revolutionary treatment method in a wide variety of different conditions and illnesses.   Moreover, as the prospects for a COVID-19-free world fade from the immediate horizon, MesenCure may be the key to lowering rates of severe illness and hospitalization in order to keep public health systems within their capacities while preventing further rounds of withering economic closures against the backdrop of the Delta variant’s global surge. 

About Bonus BioGroup

Since its establishment, Bonus BioGroup has worked to develop cell therapies and tissue-engineered products for bone regeneration. The main component of the viable bone graft developed by the Company are mesenchymal stromal cells isolated from the patient’s adipose tissue. During the outbreak of the COVID-19 pandemic, the Company started to study these mesenchymal cells and their potential applications to attenuating the associated hyper-inflammatory response (i.e., cytokine storm) provoked by COVID-19 and other diseases. In the development of MesenCure, Bonus BioGroup applied a variety of unique technologies and proprietary knowledge, some of which are currently in development by the Company, and some of which are part of the Company’s broad intellectual property portfolio.

Forward-Looking Statement

Bonus BioGroup’s assessments regarding the therapeutic effect of MesenCure and/or its marketing potential, the Company’s ability to continue the development of the drug product, including the conduction of clinical trials, and the attaining of a drug product that can be medically applied in humans, for the time periods expected to conduct any stages in any trial, are a forward-looking statement, as defined by the in the securities law 1968, which is based on the Company’s estimates and on the information in its possession at the time of reporting.

There is no certainty that this information will be realized, in whole or in part, among others, due to dependence on third parties actions that are not under the control of the Company, the possibility of delay in obtaining relevant regulatory approvals, and/or a change in the relevant conditions and/or feasibility studies that the Company may conduct, and/or delay in conducting of studies and/or the need for further studies and/or failure of studies and/or technological changes and/or development and marketing of similar and/or more effective competing products and/or lack of availability of resources and/or realization of any of the risk factors related to research and/or trials and/or its results.

SOURCE: Bonus BioGroup

Reference Link : https://www.bonusbiogroup.com/index.php/news-media/press-releases/item/40-the-israeli-ministry-of-health-approved-the-joining-of-additional-medical-centers-to-the-phase-ii-clinical-trial-for-severe-covid-19-evaluating-bonus-biogroup-s-product-mesencure

Media Contact

Company Name :- Bonus BioGroup
Email Id :- [email protected]
Company Website :- https://www.bonusbiogroup.com

The post Bonus BioGroup Receives Approval to Expand Phase-II Clinical Trials for its COVID-19 Treatment to Medical Centers Across Israel appeared first on Zex PR Wire.

Information contained on this page is provided by an independent third-party content provider. Binary News Network and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]

Share0
previous post
Daemon Doge Releases the Next 100x Return Altcoin Private Sale. Dodge Demon Giveaway included
next post
DIKE.FINANCE – A TRANSPARENT, PRIVATE, AND SECURED-CREDIT DECENTRALIZED TRADING PLATFORM
Binary News Network

Related posts

The team of Dx developers is announcing a Top Secret Game that is a P2E new mysterious NFT game

Binary News NetworkMay 17, 2022

Airplus Refrigeration, Inc. Offers Premium-Quality Ice Machines At Affordable Rental Rates for Small Restaurant and Bar Owners in Los Angeles

Binary News NetworkOctober 31, 2023

City Clinic Debuts in Spain: Redefining Integrative Healthcare with Five-Star Experience

Binary News NetworkMay 24, 2025

Recent Posts

  • Nakuja Expeditions Reveals New Custom Safari Packages for Nature Lovers and Adventure Seekers
  • Long Lake Camps Announces Exclusive 2025 Musical Theater Summer Program Featuring One-on-One Coaching – Limited Spots Remaining, Enroll Now!
  • Road Freight Transport Drives Growth in Azerbaijan’s Service Exports
  • ToonieBet launches Casino and Sportsbook platform in Ontario, Canada.
  • Avazona Ltd.’s ‘Founders in Focus’ Hits #1 Best-Seller on Amazon, Celebrating 14 Elite Entrepreneurs Who Built It Their Way

Popular posts

zkSwap Finance Announces 4 New Features that Boost...

Binary News NetworkNovember 18, 2024
November 18, 2024

Elevate Your Pet’s Happiness with Puppy Supply Online’s...

Binary News NetworkDecember 12, 2023
December 12, 2023

Raleigh Entrepreneur Lin Honeycutt Urges Focus on Skilled...

Binary News NetworkMay 19, 2025
May 19, 2025

Gold Backed IRA Is The Most Popular Stagflation...

Binary News NetworkDecember 19, 2022
December 19, 2022

The Significance of Cross-Chain Compatibility in the Blockchain...

Binary News NetworkSeptember 10, 2024
September 10, 2024

TelMDCare Revolutionizes the Healthcare Industry; Provides Access to...

Binary News NetworkMay 12, 2023
May 12, 2023
@2022 - mrjung.net. Manage by Binary News Network
Mrjung.net
FacebookTwitterInstagramGoogleYoutube
  • Ethereum
  • Bitcoin
  • Markets
  • Guides
  • Analytic
  • Exchange
  • Contact